

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER147058187US, in an envelope addressed to: MS Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 23, 2003

Signature:

*Staci Harris*  
(Staci Harris)

Docket No.: HO-P01886US2  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Ryland F. Young, et al.

Application No.: Not Yet Assigned

Group Art Unit: N/A

Filed: July 23, 2003

Examiner: Not Yet Assigned

For: ANTIBIOTICS BASED UPON  
BACTERIOPHAGE LYSIS PROTEINS

**INFORMATION DISCLOSURE STATEMENT (IDS).**

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.

The patent(s) or publications in the attached form PTO/SB/08 (facsimile) are not supplied because they were previously cited by or submitted to the Office in a prior application No. 09/626,036, filed July 27, 2000 and relied upon in this application for an earlier filing date under 35 U.S.C. 120.


While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. 10020446.

Dated: July 23, 2003

Respectfully submitted,

By 

Melissa W. Acosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1
-------	---

of 2

**Complete if Known**

Application Number	09/626,036
--------------------	------------

Filing Date	07/27/2000
-------------	------------

First Named Inventor	YOUNG
----------------------	-------

Group Art Unit

Examiner Name \_\_\_\_\_

Attorney Docket Number	P01886US1
------------------------	-----------

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

5570657.1

Please type a plus sign (+) inside this box → ☐

PTO/SB/06A (10-95)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 2

**Complete if Known**

Application Number	09/626,036
Filing Date	07/27/2000
First Named Inventor	YOUNG
Group Art Unit	
Examiner Name	
Attorney Docket Number	P01886US1

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ROOF, et al., Mutational Analysis of <i>slpD</i> , an <i>Escherichia coli</i> Gene Encoding a Protein of the FKBP Immunophilin Family, <i>Molecular Microbiology</i> 25(6), 1997, p. 1031-1046.	
		ROOF, et al., <i>slpD</i> , a Host Gene Required for (ph)X174 Lysis, Is Related to the FK506-binding Protein Family of Peptidyl-prolyl cis-trans-isomerases, <i>The Journal of Biological Chemistry</i> 269(4), January 28, 1994, p. 2902-2910.	
		SMITH, et al., The (lambda) Holin Accumulates Beyond the Lethal Triggering Concentration under Hyperepression Conditions, <i>Gene Expression Vol. 7</i> , 1998, p. 39-52.	
		WINTER AND GOLD, Overproduction of Bacteriophage Q(beta) Maturation (A2) Protein Leads to Cell Lysis, <i>Cell Vol. 33</i> , July 1983, p. 877-885.	
		HARA, et al., A Promoter for the First Nine Genes of the <i>Escherichia coli</i> <i>mra</i> Cluster of Cell Division and Cell Envelope Biosynthesis Genes, Including <i>ftsI</i> and <i>ftsW</i> , <i>Journal of Bacteriology</i> 179(16), September 1997, p. 5802-5811.	
		BERNHARDT, et al., Genetic evidence that the bacteriophage (ph)X174 lysis protein inhibits cell wall synthesis, <i>PNAS</i> 97(8), April 11, 2000, p. 4297-4302.	
		FURSTE, et al., Molecular cloning of the plasmid RP4 primase region in a multi-host-range <i>lacP</i> expression vector, <i>Gene Vol. 48</i> , 1986, p. 119-131.	
		MENGIN-LECREULX, et al., Contribution of the <i>Pmra</i> Promoter to Expression of Genes in the <i>Escherichia coli</i> <i>mra</i> Cluster of Cell Envelope Biosynthesis and Cell Division Genes, <i>Journal of Bacteriology</i> 180(17), 1998, p. 4406-4412.	
		KLECKNER, et al., Uses of Transposons with Emphasis on Tn10, <i>Methods in Enzymology Vol. 204</i> , 1991, p. 139-180.	
		MILLER, et al., Episome Transfers: Direct Selection in A Short Course in Bacterial Genetics: A Laboratory Manual & Handbook for <i>Escherichia coli</i> and Related Bacteria (Cold Spring Harbor Lab. Press, Plainview, NY, p. 82-85, 1992.	
		BOYLE and DONACHE, <i>mraY</i> Is an Essential Gene for Cell Growth in <i>Escherichia coli</i> , <i>Journal of Bacteriology, American Society for Microbiology</i> , Dec. 1998, Vol. 180, No. 23, p. 6429-6432.	

Examiner Signature	Date Considered
-----------------------	--------------------

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>2</sup> Unique citation designation number. <sup>3</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.